Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Esophageal NeoplasmsHead and Neck NeoplasmsGastrointestinal NeoplasmsDigestive System DiseasesDigestive System NeoplasmsEsophageal DiseasesNeoplasms by SiteGastrointestinal DiseasesNeoplasms
Interventions
DEVICE

"BRAXX Esophageal Brachytherapy Applicator."

The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.

RADIATION

Add-on of intraluminal brachytherapy

Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.

Trial Locations (1)

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV